Avid Bioservices, Inc. (CDMO): Price and Financial Metrics


Avid Bioservices, Inc. (CDMO): $15.33

0.07 (+0.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CDMO POWR Grades


  • CDMO scores best on the Growth dimension, with a Growth rank ahead of 93.63% of US stocks.
  • CDMO's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • CDMO ranks lowest in Value; there it ranks in the 3rd percentile.

CDMO Stock Summary

  • CDMO's current price/earnings ratio is 139.91, which is higher than 95.71% of US stocks with positive earnings.
  • With a year-over-year growth in debt of 747.79%, Avid Bioservices Inc's debt growth rate surpasses 98.02% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Avid Bioservices Inc is reporting a growth rate of 289.71%; that's higher than 92.65% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Avid Bioservices Inc, a group of peers worth examining would be CLB, XOMA, BLNK, PLBY, and CHCI.
  • CDMO's SEC filings can be seen here. And to visit Avid Bioservices Inc's official web site, go to avidbio.com.

CDMO Valuation Summary

  • CDMO's price/sales ratio is 15.4; this is 305.26% higher than that of the median Healthcare stock.
  • Over the past 243 months, CDMO's EV/EBIT ratio has gone up 130.4.
  • Over the past 243 months, CDMO's price/earnings ratio has gone up 461.6.

Below are key valuation metrics over time for CDMO.

Stock Date P/S P/B P/E EV/EBIT
CDMO 2021-08-31 15.4 19.1 446.4 115.5
CDMO 2021-08-30 15.4 19.0 445.6 115.3
CDMO 2021-08-27 15.4 19.0 444.9 115.1
CDMO 2021-08-26 15.3 18.8 441.0 114.0
CDMO 2021-08-25 15.8 19.5 457.4 118.4
CDMO 2021-08-24 15.4 18.9 443.8 114.8

CDMO Growth Metrics

    The year over year price growth rate now stands at 266.64%.
  • Its year over year revenue growth rate is now at 60.58%.
  • The 2 year cash and equivalents growth rate now stands at -15.67%.
CDMO's revenue has moved up $62,374,000 over the prior 34 months.

The table below shows CDMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 115.977 26.713 9.775
2021-09-30 106.275 26.71 8.292
2021-06-30 101.23 26.513 5.612
2021-03-31 95.868 31.182 3.318
2020-12-31 80.812 16.369 -0.955
2020-09-30 72.591 10.544 -5.266

CDMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDMO has a Quality Grade of C, ranking ahead of 27.37% of graded US stocks.
  • CDMO's asset turnover comes in at 0.495 -- ranking 83rd of 682 Pharmaceutical Products stocks.
  • COCP, HROW, and IBIO are the stocks whose asset turnover ratios are most correlated with CDMO.

The table below shows CDMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 0.495 0.318 0.126
2021-04-30 0.587 0.306 0.157
2021-01-31 0.653 0.246 0.079
2020-10-31 0.672 0.199 0.002
2020-07-31 0.659 0.163 -0.044
2020-04-30 0.568 0.066 -0.173

CDMO Price Target

For more insight on analysts targets of CDMO, see our CDMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.25 Average Broker Recommendation 1.38 (Strong Buy)

CDMO Stock Price Chart Interactive Chart >

Price chart for CDMO

CDMO Price/Volume Stats

Current price $15.33 52-week high $34.51
Prev. close $15.26 52-week low $11.30
Day low $14.84 Volume 487,400
Day high $15.72 Avg. volume 626,925
50-day MA $13.69 Dividend yield N/A
200-day MA $21.29 Market Cap 946.54M

Avid Bioservices, Inc. (CDMO) Company Bio


Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate includes bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company was founded in 1981 and is based in Tustin, California.


CDMO Latest News Stream


Event/Time News Detail
Loading, please wait...

CDMO Latest Social Stream


Loading social stream, please wait...

View Full CDMO Social Stream

Latest CDMO News From Around the Web

Below are the latest news stories about Avid Bioservices Inc that investors may wish to consider to help them evaluate CDMO as an investment opportunity.

Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Avid (CDMO) to Report Q3 Earnings: What's in the Cards?

Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.

Yahoo | February 21, 2022

Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know

Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.

Yahoo | February 16, 2022

Avid Bioservices (CDMO) Stock Moves -1.6%: What You Should Know

In the latest trading session, Avid Bioservices (CDMO) closed at $21.54, marking a -1.6% move from the previous day.

Yahoo | February 10, 2022

Here's Why Avid Bioservices (NASDAQ:CDMO) Can Manage Its Debt Responsibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | February 4, 2022

Read More 'CDMO' Stories Here

CDMO Price Returns

1-mo 14.32%
3-mo -21.55%
6-mo -34.23%
1-year -41.38%
3-year 156.35%
5-year 247.62%
YTD -47.46%
2021 152.86%
2020 50.46%
2019 87.07%
2018 5.67%
2017 78.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7042 seconds.